These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32541326)

  • 21. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
    J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
    World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capecitabine Extends Survival for Biliary Tract Cancer.
    Cancer Discov; 2017 Jul; 7(7):OF1. PubMed ID: 28572460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
    Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
    Zheng T; Jin J; Zhou L; Zhang Y
    Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
    Konishi M
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):301-5. PubMed ID: 22262202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
    Kish M; Chan K; Perry K; Ko YJ
    Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study).
    Kobayashi S; Wada H; Sakai D; Baba H; Kanai M; Kamachi H; Takayama T; Ueno M; Takahashi M; Sho M; Yoshimura K; Hatano E; Nagano H; Ioka T;
    Oncology; 2024; 102(6):447-456. PubMed ID: 38048759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Non-surgical treatment for pancreatic cancer].
    Okusaka T; Ueno H; Ikeda M; Morizane C
    Nihon Shokakibyo Gakkai Zasshi; 2006 Apr; 103(4):391-7. PubMed ID: 16629457
    [No Abstract]   [Full Text] [Related]  

  • 36. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
    Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
    Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
    Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
    J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
    Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.